皮质c [11] PBR28宠物小胶质炎症指标解释认知能力的差异(S41.005)女士的人

文摘

摘要目的:描述先天大脑MRI炎症反应的关系标记病理学和残疾的多发性硬化症(MS)。背景:慢性小胶质激活导致神经退化在女士我们使用c [11] PBR28宠物评估激活小胶质负担。方法:24女士志愿者(17 RR: 7 SP MS)和11个健康志愿者接受了PET扫描和c [11] PBR28 3 t磁共振成像。在女士,T2白质病变(WML), DIR皮质病变(CL)和正常白质(NAWM) MRI分割。c [11] PBR28分布体积比(DVR)估计洛根图解法和尾参考区域。正常化通用卷计算使用SIENAX(目前工具箱)。残疾是评估使用eds和简短的国际认知评估女士(BICAMS)电池。结果:意味着在NAWM DVR(意思是+ / - SD, 1.27 + / - 0.25)大于WML(1.03 + / - 0.26)和WM健康对照组(0.99 + / - 0.13,与p < 4 x10-4)。之间没有区别病人女士生皮质DVR(1.41 + / - 0.20)和控制(1.33 + / - 0.17,p = 0.284),但患者更高的皮质DVR女士当正常皮质体积(0.25 + / - 0.06和0.21 + / - 0.04,p < 0.05)。BICAMS和eds相关整个通用卷(枪兵的ρ= 0.45,p = 0.028和ρ= -0.41,p = 0.049)。eds并不与c [11] PBR28吸收。然而,BICAMS相关DVR在皮层(ρ= -0.432,p = 0.035)和CL(ρ= -0.50,p = 0.013)和皮质DVR正常化皮质体积(ρ= - 0.42,p = 0.041)结论:c [11] PBR28强调了相关性小胶质整个皮质和CL认知损伤的炎症的扩散激活先天免疫女士可以解释方面残疾不占T2病灶负载。

披露:达塔博士已经收到葛兰素史克的研究支持。Battaglini博士没有披露。斯科特博士没有披露。Yaldizli博士已经收到个人活动与Teva补偿和拜耳先灵葆雅作为一个演讲者。Santos-Ribeiro博士没有披露。拉宾博士已经收到个人活动与葛兰素史克公司补偿,BioTie, Gedeon Richter Teva神经科学,Lighlake疗法担任顾问和发言人。拉宾博士接到Abbvie研究支持。拉宾博士持有股票和/或Gunn博士已经收到个人赔偿葛兰素史克,Abbvie UCB制药,来担任顾问。欧文博士没有披露。马利克博士已经收到个人活动与补偿Idec,诺华,和默克/ Serono。 Dr. Ciccarelli has received personal compensation for activities with Novartis, Biogen and GE as a consultant. Dr. St. John Nicholas has received personal compensation for activities with Bayer Pharmaceuticals Corporation as a speaker, and Biogen Idec as a principal investigator, researcher, speaker and for serving on the advisory board. Dr. Landgon has receiverd personal compensation for activities with Bayer Schering Pharma AG/Bayer HealthCare Pharmaceuticals, Biogen, and Hoffman. Dr. De Stefano has received personal compensation for activities with Schering, Biogen Idec, Teva, Novartis, Genzyme, and Merk Serono S.A. for consulting services, speaking and travel support and for activities with Merk Serono S.A. as an advisory board m Dr. Matthews has received personal compensation for activities with Biogen, Novartis, Ixico, transparency Life Sciences, and Adelphi Communications. Dr. Matthews has received research support from GlaxoSmithKline and Biogen.